
Miwako Kobayashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11939447/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021. Journal of Infectious Diseases, 2022, 225, 1694-1700.	4.0	14
2	Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ, The, 2022, 376, e069761.	6.0	393
3	Coronavirus Disease 2019 (COVID-19) in Americans Aboard the Diamond Princess Cruise Ship. Clinical Infectious Diseases, 2021, 72, e448-e457.	5.8	34
4	Use of US Public Health Travel Restrictions during COVID-19 Outbreak on Diamond Princess Ship, Japan, February–April 2020. Emerging Infectious Diseases, 2021, 27, 710-718.	4.3	3
5	Use of Real-Time PCR for <i>Chlamydia psittaci</i> Detection in Human Specimens During an Outbreak of Psittacosis — Georgia and Virginia, 2018. Morbidity and Mortality Weekly Report, 2021, 70, 505-509.	15.1	18
6	Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines. Epidemiology, 2021, 32, 508-517.	2.7	84
7	Physician survey regarding updated <scp>PCV13</scp> vaccine recommendations for adults ≥65 years. Journal of the American Geriatrics Society, 2021, 69, 2612-2618.	2.6	3
8	Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1156-1162.	15.1	197
9	Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1337-1343.	15.1	358
10	Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions. Human Vaccines and Immunotherapeutics, 2021, 17, 2232-2240.	3.3	1
11	Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA - Journal of the American Medical Association, 2021, 326, 2043.	7.4	458
12	Impact of 10-valent Pneumococcal Conjugate Vaccine Introduction on Pneumococcal Carriage and Antibiotic Susceptibility Patterns among Children aged <5 Years and Adults with HIV Infection, Kenya 2009–2013. Clinical Infectious Diseases, 2020, 70, 814-826.	5.8	11
13	Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine, 2020, 38, 1770-1777.	3.8	25
14	Enhanced contact investigations for nine early travel-related cases of SARS-CoV-2 in the United States. PLoS ONE, 2020, 15, e0238342.	2.5	22
15	Occupational Respiratory Infections. Clinics in Chest Medicine, 2020, 41, 739-751.	2.1	4
16	Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020. Morbidity and Mortality Weekly Report, 2020, 69, 347-352.	15.1	301
17	Psittacosis Outbreak among Workers at Chicken Slaughter Plants, Virginia and Georgia, USA, 2018. Emerging Infectious Diseases, 2019, 25, 2143-2145.	4.3	34
18	WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016. Vaccine, 2019, 37, 7307-7314.	3.8	74

Μιwako Kobayashi

#	Article	IF	CITATIONS
19	Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 2019, 68, 1069-1075.	15.1	254
20	The Effect of Text Message Reminders to Health Workers on Quality of Care for Malaria, Pneumonia, and Diarrhea in Malawi: A Cluster-Randomized, Controlled Trial. American Journal of Tropical Medicine and Hygiene, 2019, 100, 460-469.	1.4	4
21	Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique, 2001–2015. PLoS ONE, 2018, 13, e0191193.	2.5	30
22	Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged <5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine — Kenya, 2009–2010. BMC Infectious Diseases, 2017, 17, 25.	2.9	32
23	Compendium of Measures to Control <i>Chlamydia psittaci</i> Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2017. Journal of Avian Medicine and Surgery, 2017, 31, 262-282.	0.5	118
24	Pneumococcal Serotype 5 Colonization Prevalence Among Newly Arrived Unaccompanied Children 1 Year After an Outbreak—Texas, 2015. Pediatric Infectious Disease Journal, 2017, 36, 236-238.	2.0	3
25	Health worker adherence to malaria treatment guidelines at outpatient health facilities in southern Malawi following implementation of universal access to diagnostic testing. Malaria Journal, 2017, 16, 40.	2.3	42
26	Quality of Case Management for Pneumonia and Diarrhea Among Children Seen at Health Facilities in Southern Malawi. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1107-1116.	1.4	12
27	Multistate Outbreak of Respiratory Infections Among Unaccompanied Children, June 2014–July 2014. Clinical Infectious Diseases, 2016, 63, 48-56.	5.8	8
28	Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. F1000Research, 2016, 5, 2355.	1.6	64
29	Diagnosis of Tuberculosis by Using a Nucleic Acid Amplification Test in an Urban Population with High HIV Prevalence in the United States. PLoS ONE, 2014, 9, e107552.	2.5	4
30	Rare Elizabethkingia meningosepticum meningitis case in an immunocompetent adult. Emerging Microbes and Infections, 2013, 2, 1-4.	6.5	12